Myriad Genetics (NASDAQ:MYGN) announced its quarterly earnings data on Monday. The company reported $0.31 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.07, Bloomberg Earnings reports. The firm had revenue of $194.00 million for the quarter, compared to analyst estimates of $188.72 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company earned $0.26 EPS.

Myriad Genetics (NASDAQ MYGN) opened at $35.81 on Wednesday. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $41.57. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The stock has a market capitalization of $2,381.88, a price-to-earnings ratio of 31.56, a PEG ratio of 2.17 and a beta of 0.32.

A number of brokerages have commented on MYGN. BTIG Research set a $41.00 price objective on Myriad Genetics and gave the company a “buy” rating in a research report on Tuesday, January 16th. BidaskClub upgraded Myriad Genetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 20th. Goldman Sachs Group began coverage on Myriad Genetics in a research report on Monday, January 29th. They issued a “sell” rating and a $32.00 price objective on the stock. ValuEngine lowered Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Finally, Barclays reiterated a “hold” rating and issued a $30.00 price objective on shares of Myriad Genetics in a research report on Monday, January 8th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $30.67.

In other news, VP Richard M. Marsh sold 37,654 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $40.25, for a total value of $1,515,573.50. Following the transaction, the vice president now directly owns 157,648 shares in the company, valued at approximately $6,345,332. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander Ford sold 3,031 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $31.64, for a total value of $95,900.84. The disclosure for this sale can be found here. Insiders sold a total of 71,064 shares of company stock worth $2,679,097 over the last 90 days. 6.70% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/myriad-genetics-mygn-announces-earnings-results-2/1850794.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Earnings History for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.